New Delhi:
Leading biotechnology company Biocon has recently introduced a groundbreaking product in the UK for managing diabetes and obesity.
The GLP-1 peptide, known as Liraglutide, will be available in the UK under the brand names Liraglutide Biocon for diabetes treatment and Biolide for chronic weight management, as announced by the company in a press release.
This launch comes after receiving approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK earlier this year, marking Biocon Ltd as the first generics company to secure approval for gLiraglutide in a major regulated market.
“The timely introduction of this product will provide healthcare providers and patients with affordable access to this medication, addressing an unmet need,” stated Biocon CEO and MD Siddharth Mittal.
The company’s focus will now be on expanding the availability of gLiraglutide in other European markets, the US, and selected regions, Mittal added.
GLP-1 medications help in reducing blood sugar levels and promoting weight loss, with Liraglutide being a synthetic analog of the GLP-1 peptide that is administered through a once-daily injection.
Shares of Biocon were trading at Rs 302.15 apiece on BSE, experiencing a 3.17% decrease.
(The content of this article, apart from the headline, has not been altered by NDTV staff and is sourced from a syndicated feed.)
